A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.

Published on Jun 5, 2020in Journal of Medical Virology2.327
· DOI :10.1002/JMV.26141
Zhicheng Zhang3
Estimated H-index: 3
,
Shumei Wang1
Estimated H-index: 1
+ 9 AuthorsHongyi Chen3
Estimated H-index: 3
Sources
Abstract
BACKGROUND: In late December 2019, the coronavirus disease 2019�(COVID-19) first outbroke in Wuhan city, China, and has now become a global pandemic. However, there is no specific antiviral treatment for COVID-19. METHODS: This study enrolled 33 COVID-19 patients in the nineth hospital of Nanchang from January 27th to February 24th , 2020. Clinical indexes of patients upon admission/discharge were examined. Patients were divided into two groups according to different treatment plans (Danoprevir; Lopinavir/Ritonavir). The days to achieve negative nucleic acid testing and the days of hospital stays were counted and statistically analyzed. RESULTS: COVID-19 patients treated with Danoprevir or Lopinavir/Ritonavir were all improved and discharged. Indexes like blood routine, inflammation and immune-related indexes were significantly recovered after treatment. Additionally, under the circumstance that there was no significant difference in patients' general information between the two groups, we found that the mean time to achieve negative nucleic acid testing and hospital stays of patients treated with Danoprevir both were significantly shorter than those of patients with Lopinavir/Ritonavir. CONCLUSION: Collectively, applying Danoprevir is a good treatment plan for COVID-19 patients. This article is protected by copyright. All rights reserved.
📖 Papers frequently viewed together
20211.06medRxiv
5 Authors (Xiu Lan, ..., Yanyan Xu)
2020
5 Authors (G. Guo, ..., X. Zhang)
References19
Newest
#1Xinyi Chen (Qingdao University)H-Index: 1
#2Yi YangH-Index: 1
Last. Yanyun WanH-Index: 1
view all 10 authors...
Abstract Coronavirus disease 2019 (COVID-19) broke out in Wuhan, Hubei, China in December 2019. Tens thousands of people have been infected with the disease. Our aim was to distinguish severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive patients from SARS-CoV-2-negative patients. We retrospectively compared the data of COVID-19 patients with those of suspected and confirmed SARS-CoV-2-negative patients (control patients). There were 78 COVID-19 patients and 26 control patients,...
Source
#1Taisheng Li (Peking Union Medical College Hospital)H-Index: 30
#2Hongzhou LuH-Index: 33
Last. Wenhong Zhang (Fudan University)H-Index: 42
view all 3 authors...
ABSTRACTThree leading infectious disease experts in China were invited to share their bedside observations in the management of COVID-19 patients. Professor Taisheng Li was sent to Wuhan to provide...
Source
#1Hongyi ChenH-Index: 3
#2Zhicheng ZhangH-Index: 3
Last. Jinzi J. WuH-Index: 2
view all 8 authors...
As coronavirus disease 2019 (COVID-19) outbreak, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), started in China in January, 2020, repurposing approved drugs is emerging as important therapeutic options. We reported here the first clinical study using hepatitis C virus (HCV) protease inhibitor, danoprevir, to treat COVID-19 patients. Danoprevir (Ganovo) is a potent HCV protease (NS3/4A) inhibitor (IC50 = 0.29 nM), which was approved and marketed in China since 2018 t...
Source
#1Jianjun Gao (Qingdao University)H-Index: 20
#2Zhenxue TianH-Index: 1
Last. Xu YangH-Index: 1
view all 3 authors...
The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, andscientists are endeavoring to discover drugs for its efficacious treatment inChina. Chloroquine phosphate, an old drug for treatment of malaria, is shown tohave apparent efficacy and acceptable safety against COVID-19 associatedpneumonia in multicenter clinical trials conducted in China. The drug isrecommended to be included in the next version of the Guidelines for thePrevention, Diagnosis, and Treatment of Pneumonia Caused ...
Source
There is a new public health crises threatening the world with the emergence and spread of 2019 novel coronavirus (2019-nCoV) or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus originated in bats and was transmitted to humans through yet unknown intermediary animals in Wuhan, Hubei province, China in December 2019. There have been around 96,000 reported cases of coronavirus disease 2019 (COVID-2019) and 3300 reported deaths to date (05/03/2020). The disease is transmi...
Source
#1Zhenwei Wang (SHU: Shanghai University)H-Index: 1
#2Xiaorong ChenH-Index: 2
Last. Wei Zhang (SHU: Shanghai University)H-Index: 1
view all 5 authors...
Pneumonia associated with the 2019 novel coronavirus (2019-nCoV) is continuouslyand rapidly circulating at present. No effective antiviral treatment has beenverified thus far. We report here the clinical characteristics and therapeuticprocedure for four patients with mild or severe 2019-nCoV pneumonia admitted toShanghai Public Health Clinical Center. All the patients were given antiviraltreatment including lopinavir/ritonavir (Kaletra((R))), arbidol, and ShufengJiedu Capsule (SFJDC, a tradition...
Source
#1Tian-Tian Yao (PKU: Peking University)H-Index: 2
#2Jian-Dan Qian (PKU: Peking University)H-Index: 2
Last. Gui-Qiang Wang (PKU: Peking University)H-Index: 2
view all 5 authors...
Abstract In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the SARS and MERS epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the...
Source
#1Hussin A. Rothan (GSU: Georgia State University)H-Index: 23
#2Siddappa N. Byrareddy (NU: University of Nebraska–Lincoln)H-Index: 22
Abstract Coronavirus disease (COVID-19) is caused by SARS-COV2 and represents the causative agent of a potentially fatal disease that is of great global public health concern. Based on the large number of infected people that were exposed to the wet animal market in Wuhan City, China, it is suggested that this is likely the zoonotic origin of COVID-19. Person-to-person transmission of COVID-19 infection led to the isolation of patients that were subsequently administered a variety of treatments....
Source
#1Jasper Fuk-Woo Chan (HKU: University of Hong Kong)H-Index: 90
#2Shuofeng Yuan (Li Ka Shing Faculty of Medicine, University of Hong Kong)H-Index: 30
Last. Kwok-Yung Yuen (HKU: University of Hong Kong)H-Index: 159
view all 21 authors...
Summary Background An ongoing outbreak of pneumonia associated with a novel coronavirus was reported in Wuhan city, Hubei province, China. Affected patients were geographically linked with a local wet market as a potential source. No data on person-to-person or nosocomial transmission have been published to date. Methods In this study, we report the epidemiological, clinical, laboratory, radiological, and microbiological findings of five patients in a family cluster who presented with unexplaine...
Source
#1Yi Chi Wu (Taipei Veterans General Hospital)H-Index: 2
#2Ching Sung Chen (Taipei Veterans General Hospital)H-Index: 2
Last. Yu Jiun Chan (NYMU: National Yang-Ming University)H-Index: 8
view all 3 authors...
In late December 2019, a previous unidentified coronavirus, currently named as the 2019 novel coronavirus#, emerged from Wuhan, China, and resulted in a formidable outbreak in many cities in China and expanded globally, including Thailand, Republic of Korea, Japan, United States, Philippines, Viet Nam, and our country (as of 2/6/2020 at least 25 countries). The disease is officially named as Coronavirus Disease-2019 (COVID-19, by WHO on February 11, 2020). It is also named as Severe Pneumonia wi...
Source
Cited By8
Newest
#1Fryad Rahman (University of Sulaymaniyah)H-Index: 5
#2Camille Libre (University of Lyon)H-Index: 1
Last. Sergey Tcherniuk (University of Paris)
view all 4 authors...
Human respiratory syncytial virus (hRSV) is a major cause of respiratory illness in young children and can cause severe infections in the elderly or in immunocompromised adults. To date, there is no vaccine to prevent hRSV infections, and disease management is limited to preventive care by palivizumab in infants and supportive care for adults. Intervention with small-molecule antivirals specific for hRSV represents a good alternative, but no such compounds are currently approved. The investigati...
Source
Objectives: To systematically review the clinical literature reporting the use of Lopinavir/ritonavir (LPV/r) for the treatment of patients with COVID-19 to assess the efficacy of LPV/r for the treatment of Cornonavirus disease 19 (COVID-19). Methods: The authors systematically searched PubMed and MedRxiv databases for studies describing treatment of COVID-19 patients using LPV/r compared to other therapies. Articles were excluded if they were case reports, opinion editorials, preclinical studie...
Source
#1Aura RusuH-Index: 11
Last. Octavia-Laura MoldovanH-Index: 1
view all 4 authors...
Source
#1Paola Magro (University of Brescia)H-Index: 8
#2Isabella Zanella (University of Brescia)H-Index: 16
Last. Eugenia Quiros-Roldan (University of Brescia)H-Index: 29
view all 5 authors...
Currently, there is no specific antiviral treatment for COVID-19. However, drugs previously developed to treat other viral infections are being tested to verify if they might also be effective against SARS-CoV-2, the virus that causes COVID-19. Twenty years ago, the F.D.A. approved Lopinavir/ritonavir (LPV/r) to treat HIV infection. LPV and ritonavir were initially purposed to inhibit 3-chymotrypsin-like protease (3CLpro) of SARS-CoV and MERS-CoV and preliminary promising data on its efficacy fo...
Source
#1Dene R. Littler (Monash University, Clayton campus)H-Index: 19
#2Bruce J. MacLachlan (Monash University, Clayton campus)H-Index: 6
Last. Benjamin S. Gully (Monash University, Clayton campus)H-Index: 9
view all 5 authors...
The race to identify a successful treatment for COVID19 will be defined by fundamental research into the replication cycle of the SARS-CoV-2 virus. This has identified five distinct stages from which numerous vaccination and clinical trials have emerged alongside an innumerable number of drug discovery studies currently in development for disease intervention. Informing every step of the viral replication cycle has been an unprecedented 'call-to-arms' by the global structural biology community. ...
Source
#1Getu Zhaori (Capital Medical University)H-Index: 1
#2Lu Lu (Capital Medical University)H-Index: 1
Last. Yongli Guo (Capital Medical University)H-Index: 1
view all 4 authors...
Antiviral therapy with antiviral agents is a very important component of treatment for the 2019 novel coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It is important to clarify how to evaluate efficacy and safety of antiviral agents in treatment of COVID-19 during the pandemic of this disease. We need to answer the following questions: do we still need to use rigorously designed randomized controlled clinical trials (RCTs)? Or, will it b...
Source
#1Desh Deepak Singh (Amity Institute of Biotechnology)H-Index: 14
#2Ihn Han (Kwangwoon University)H-Index: 14
Last. Dharmendra K. Yadav (Gachon University)H-Index: 20
view all 4 authors...
The coronavirus (SARS-CoV-2) pandemic is a rapidly transmitting and highly pathogenic disease. The spike protein of SARS-CoV-2 binds to the surface of angiotensin-converting enzyme-2 (ACE2) receptors along the upper respiratory tract and intestinal epithelial cells. SARS-CoV-2 patients develop acute respiratory distress, lymphocytic myocarditis, disseminated intravascular coagulation, lymphocytic infiltration, and other serious complications. A SARS-CoV-2 diagnosis is conducted using quantitativ...
Source
#1Yan-feng Pan (Zhengzhou University)H-Index: 7
#2Qingqing Li (Zhengzhou University)H-Index: 2
Last. Li Sun (Zhengzhou University)
view all 11 authors...
The aim of the present study was to identify the risk factors associated with prolonged shedding in patients with coronavirus disease 2019 (COVID-19), and to evaluate the effects of current clinical and clinicopathological factors on viral shedding in patients. A total of 186 COVID-19 inpatients were enrolled in this multicentre retrospective analysis. Detailed clinical data of each patient were collected, and the factors that affected the duration of viral shedding were retrospectively analysed...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.